US20090197964A1 - Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage - Google Patents
Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage Download PDFInfo
- Publication number
- US20090197964A1 US20090197964A1 US12/322,434 US32243409A US2009197964A1 US 20090197964 A1 US20090197964 A1 US 20090197964A1 US 32243409 A US32243409 A US 32243409A US 2009197964 A1 US2009197964 A1 US 2009197964A1
- Authority
- US
- United States
- Prior art keywords
- subject
- citrulline
- nitric oxide
- vasospasm
- sah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the presently disclosed subject matter relates to the treatment of Aneurysmal Subarachnoid Hemorrhage (SAH), complications associated with SAH (including vasospasm), and vasospasm associated with atherosclerosis, including but not limited to that associated with coronary arterial disease.
- SAH Aneurysmal Subarachnoid Hemorrhage
- complications associated with SAH including vasospasm
- vasospasm associated with atherosclerosis
- SAH Aneurysmal Subarachnoid Hemorrhage
- SAH is a major concern throughout the world, with varying incidences of between about 1 and 96 incidents per 100,000 person/year (Batista da Costa Jr. et al. (2004) Arq Neuro - Psiquiatr (Sao Paulo) 62:245-249), with a worldwide incidence of about 10 per 100,000 person/year (Batista da Costa Jr. et al. (2004) Arq Neuro - Psiquiatr (Sao Paulo) 62:245-249). According to Suarez et al., SAH affects 21,000-33,000 people per year in the United States, and represents about 2-5% of all new strokes (Suarez et al. (2006) N Engl J Med 354:387-396).
- an effective amount of a nitric oxide precursor is administered to a subject suffering from SAH and/or associated complications and/or at risk for suffering complications associated with SAH (e.g., vasospasm).
- the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof.
- the nitric oxide precursor, such as citrulline is administered orally.
- the nitric oxide precursor, such as citrulline is administered intravenously.
- the subject to be treated is a subject suffering from vasospasm.
- the subject to be treated is a subject suffering from an acute condition associated with vasospasm.
- the presently disclosed subject matter also provides methods and compositions for treating vasospasm.
- the subject to be treated suffers from vasospasm associated with SAH.
- the subject to be treated has suffered trauma that results in vasospasm (e.g., trauma that results in SAH).
- the methods can comprise administering to a subject in need thereof an effective amount of a nitric oxide precursor.
- the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof.
- the subject to be treated is suffering from vasospasm associated with SAH.
- the nitric oxide precursor, such as citrulline is administered orally.
- the nitric oxide precursor, such as citrulline is administered intravenously.
- FIG. 1 is a schematic of the urea cycle.
- SAH Aneurysmal Subarachnoid Hemorrhage
- the in vivo synthetic pathway for arginine commences with ornithine. Ornithine is combined with carbamyl phosphate to produce citrulline, which in turn is combined with aspartate, in the presence of adenosine triphosphate (ATP), to produce argininosuccinate. In the final step, fumarate is split from argininosuccinate, to produce arginine.
- the degradative pathway for arginine is by the hydrolytic action of arginase, to produce ornithine and urea. These reactions form the urea cycle.
- the urea cycle serves as the primary pathway for removing waste nitrogen produced by the metabolism of endogenous and exogenous proteins, and is shown schematically in FIG. 1 . In addition to its role in nitrogen clearance, the urea cycle is the body's intrinsic source of arginine which acts as a precursor of nitric oxide (NO), a potent vasodilator.
- NO nitric oxide
- SAH typically results from rupture of a cranial aneurysm which results in leakage of blood into compartments of the nervous system that contain cerebrospinal fluid.
- Primary symptomology typically includes sudden onset of headache, which is usually very severe, nausea, vomiting, neck pain, photophobia, and loss of consciousness (Suarez et al. (2006) N Engl J Med 354:387-396), which is frequently associated with neurological deficits that become apparent on physical exam (Suarez et al. (2006) N Engl J Med 354:387-396).
- Hydrocephalus (20%), rebleeding (7%), cerebral vasospasm (46%), seizures (30%), hyponatremia (28%), myocardial injury (35%), and pulmonary edema (23%) occur in a significant percentage of patients, even if the damage to the underlying vessel(s) is repaired. These events also frequently lead to additional secondary complications, including seizures, pulmonary edema, cardiac arrhythmias, electrolyte disturbances, and neuropsychological complications such as problems with memory, mood, and neuropsychological function.
- FT angiography and/or cerebral angiography can locate an aneurysm, which is then repaired. If, however, the angiography is normal, CT angiography is typically repeated 1-3 weeks subsequent to initial presentation, optionally followed by brain, brain stem, and/or spinal cord imaging. In those cases where heat CT does not detect a subarachnoid hemorrhage, testing of cerebrospinal fluid obtained by lumbar puncture can also provide indicators of SAH, which then can be confirmed by angiography.
- treatment generally includes securing of the aneurysm by neurosurgical clipping or endovascular coiling.
- Treatment of associated symptoms including, but not limited to hypertension, hyperthermia, hyperglycemia, and ischemia are performed as needed.
- a subject Given that complications associated with SAH typically develop over the course of several weeks, a subject generally remains hospitalized for extended periods in order to provide continuous monitoring of the subject's condition.
- the presently disclosed subject matter provides methods for treating SAH and/or associated complications in a subject.
- an effective amount of a nitric oxide precursor is administered to a subject suffering from SAH and/or associated complications and/or at risk for suffering complications associated with SAH. Representative examples of such complications are disclosed herein above.
- the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof. See FIG. 1 .
- the nitric oxide precursor is selected from the group including, but not limited to, citrulline, arginine, or combinations thereof.
- the nitric oxide precursor, such as citrulline is administered orally.
- the nitric oxide precursor, such as citrulline is administered intravenously.
- the subject to be treated is a subject suffering from vasospasm. In some embodiments, the subject to be treated is a subject suffering from an acute condition associated with vasospasm. Representative examples of such conditions are disclosed herein above.
- the subject suffering from a complication suffers from relative hypocitrullinemia.
- relative hypocitrullinemia refers to a state in which the subject suffering from a complication has reduced plasma citrulline as compared to a subject not suffering from a complication.
- the subject suffers from hypocitrullinemia.
- the hypocitrullinemia is characterized by plasma citrulline levels of ⁇ 37 ⁇ mol/liter, in some embodiments, ⁇ 25 ⁇ mol/liter, in some embodiments, ⁇ 20 ⁇ mol/liter, in some embodiments, ⁇ 10 ⁇ mol/liter, in some embodiments, ⁇ 5 ⁇ mol/liter.
- the presently disclosed subject matter also provides methods and compositions for treating vasospasm.
- the subject to be treated suffers from vasospasm associated with SAH.
- the subject to be treated has suffered trauma that results in vasospasm (e.g., trauma that results in SAH).
- the vasospasm is associated with atherosclerosis in the subject.
- the atherosclerosis is associated with coronary artery disease in the subject, with carotid arterial disease in the subject, with peripheral arterial disease in the subject, and combinations thereof.
- the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof. See FIG. 1 .
- the nitric oxide precursor is selected from the group including, but not limited to, citrulline, arginine, or combinations thereof.
- the nitric oxide precursor, such as citrulline is administered orally.
- the nitric oxide precursor, such as citrulline is administered intravenously.
- the subject to be treated is a subject suffering from vasospasm.
- the subject to be treated is a subject suffering from an acute condition associated with vasospasm (e.g. ischemia and/or angina in coronary arterial disease).
- the subject suffering from a complication suffers from relative hypocitrullinemia.
- relative hypocitrullinemia refers to a state in which the subject suffering from a complication has reduced plasma citrulline as compared to a subject not suffering from a complication.
- the phrase “treating” refers to both intervention designed to ameliorate a condition in a subject (e.g., after initiation of a disease process or after an injury) as well as to interventions that are designed to prevent the condition from occurring in the subject.
- the terms “treating” and grammatical variants thereof are intended to be interpreted broadly to encompass meanings that refer to reducing the severity of and/or to curing a condition, as well as meanings that refer to prophylaxis.
- “treating” can refer to “preventing” to any degree, or otherwise enhancing the ability of the subject to resist the process of the condition, such as a subject at risk to suffer the condition.
- the subject treated in the presently disclosed subject matter in its many embodiments is desirably a human subject, although it is to be understood that the principles of the presently disclosed subject matter indicate that the presently disclosed subject matter is effective with respect to all vertebrate species, including warm-blooded vertebrates such as mammals and birds, which are intended to be included in the term “subject”.
- a mammal is understood to include any mammalian species in which treatment is desirable, such as but not limited to agricultural and domestic mammalian species.
- mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses.
- carnivores other than humans such as cats and dogs
- swine pigs, hogs, and wild boars
- ruminants such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels
- domesticated fowl i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans.
- livestock including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.
- an effective dose of a composition of the presently disclosed subject matter is administered to a subject in need thereof.
- An “effective amount” is an amount of a composition sufficient to produce a measurable response (e.g., a biologically or clinically relevant response in a subject being treated).
- Actual dosage levels of active ingredients in the compositions of the presently disclosed subject matter can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular subject.
- the selected dosage level will depend upon the activity of the therapeutic composition, the route of administration, combination with other drugs or treatments, the severity of the condition being treated, and the condition and prior medical history of the subject being treated.
- doses of compositions can be started at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the potency of a composition can vary, and therefore an “effective amount” can vary.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the subject to be treated and the particular mode of administration.
- a formulation intended for administration to humans can contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
- the doses per person per administration are generally between 1 mg and 500 mg up to several times per day.
- dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
- the nitric oxide precursor is administered in some embodiments in a dose ranging from about 0.01 mg to about 1,000 mg, in some embodiments in a dose ranging from about 0.5 mg to about 500 mg, and in some embodiments in a dose ranging from about 1.0 mg to about 250 mg.
- the nitric oxide precursor can also be administered in some embodiments in a dose ranging from about 100 mg to about 30,000 mg, and in some embodiments in a dose ranging from about 250 mg to about 1,000 mg.
- a representative dose is 3.8 g/m2/day of arginine or citrulline (molar equivalents, MW L-citrulline 175.2, MW L-arginine 174.2).
- Representative intravenous citrulline solutions can comprise a 100 mg/ml (10%) solution.
- Representative intravenous citrulline dosages can comprise 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg.
- the dose can be decreased by an amount ranging from 50 mg/kg and 100 mg/kg to mitigate observed undesired effects on systemic blood pressure.
- doses can be administered one or more times during a given period of time, such as a day.
- a pharmaceutical composition comprises an amount of citrulline effective to raise plasma citrulline level to treat a complication as disclosed herein in a subject.
- the level is determined by comparing plasma citrulline levels in a subject to be treated to that observed in a subject not suffering from the complication.
- the amount of citrulline is effective to raise plasma citrulline level in a subject to at least 5 ⁇ mol/liter, optionally at least 10 ⁇ mol/liter, optionally at least 20 ⁇ mol/liter, optionally at least 25 ⁇ mol/liter, and optionally about 37 ⁇ mol/liter.
- the presently disclosed subject matter provides pharmaceutical compositions comprising a nitric oxide precursor and a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable carrier in humans. In some embodiments, the presently disclosed subject matter provides pharmaceutical compositions comprising citrulline or arginine in dosages as described above.
- composition of the presently disclosed subject matter is typically administered orally or parenterally in dosage unit formulations containing standard nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
- parenteral as used herein includes intravenous, intra-muscular, intra-arterial injection, or infusion techniques.
- Injectable preparations for example sterile injectable aqueous or oleaginous suspensions, are formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- Suitable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Exemplary carriers include neutral saline solutions buffered with phosphate, lactate, Tris, and the like.
- doses can be administered to a subject several times during a relevant treatment period, including but not limited to 1, 2, 3, 4, 5, 6 or more dosages.
- citrulline acting as a NO precursor can be a treatment for both SAH and coronary arterial disease through a similar mechanism of supporting vascular relaxation through restoring an adequate supply of citrulline which can act as a nitric oxide precursor amongst other actions.
- Examples 1 and 2 present the results of assaying plasma levels of citrulline, ornithine, arginine, and nitric oxide in subjects with and without vasospasm. The samples were separated by 24 hours in time from collection. In Example 1, levels were assayed after early collection, and in Example 2, levels were assayed after late collection.
Abstract
Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
Description
- This patent application is based on and claims priority to U.S. Provisional Patent Application Ser. No. 61/025,170, filed Jan. 31, 2008, the entire contents of which are herein incorporated by reference.
- The presently disclosed subject matter relates to the treatment of Aneurysmal Subarachnoid Hemorrhage (SAH), complications associated with SAH (including vasospasm), and vasospasm associated with atherosclerosis, including but not limited to that associated with coronary arterial disease.
- Aneurysmal Subarachnoid Hemorrhage (SAH) is one of the leading causes of morbidity and mortality associated with stroke worldwide. SAH is a neurological emergency characterized by extravasations of blood into spaces covering the central nervous system that are filled with cerebrospinal fluid. Several complications such as hydrocephalus, rebleeding, cerebral vasospasm, seizures, myocardial injury, and pulmonary edema can result from SAH.
- SAH is a major concern throughout the world, with varying incidences of between about 1 and 96 incidents per 100,000 person/year (Batista da Costa Jr. et al. (2004) Arq Neuro-Psiquiatr (Sao Paulo) 62:245-249), with a worldwide incidence of about 10 per 100,000 person/year (Batista da Costa Jr. et al. (2004) Arq Neuro-Psiquiatr (Sao Paulo) 62:245-249). According to Suarez et al., SAH affects 21,000-33,000 people per year in the United States, and represents about 2-5% of all new strokes (Suarez et al. (2006) N Engl J Med 354:387-396). About 80% of cases of SAH result from rupture of an intracranial aneurysm, which itself is associated with significant risk of complications, including death. The peak age of incidence is 55-60 years, and about 20% occurs between the ages of 15 and 45 years. There is a gender difference in SAH, with a female preponderance characterized by a ratio of female to male patients ranging from 1.6-4.16:1. The incidence of SAH is also higher in African-Americans than in Caucasians.
- Recent statistics indicate that about 30% of SAH patients die within the first 24 hours, and another 25-30% die within the following 4 weeks (Flett et al. (2005) AJNR Am J Neuroradiol 26:367-372). Besides the initial risks associated with SAH, a significant percentage of patients who have suffered SAH suffer from long-term cognitive impairment (Suarez et al. (2006) N Engl J Med 354:387-396), and thus SAH is associated with substantial impacts on health care resources.
- While symptom management plays a major role in the treatment of SAH, there continues to be a long felt need for treatment strategies that address the underlying physiological bases for the development of secondary complications of SAH.
- The presently disclosed subject matter provides methods and compositions for treating SAH and/or associated complications in a subject. In some embodiments, an effective amount of a nitric oxide precursor is administered to a subject suffering from SAH and/or associated complications and/or at risk for suffering complications associated with SAH (e.g., vasospasm). In some embodiments, the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof. In some embodiments, the nitric oxide precursor, such as citrulline, is administered orally. In some embodiments, the nitric oxide precursor, such as citrulline, is administered intravenously. In some embodiments, the subject to be treated is a subject suffering from vasospasm. In some embodiments, the subject to be treated is a subject suffering from an acute condition associated with vasospasm.
- The presently disclosed subject matter also provides methods and compositions for treating vasospasm. In some embodiments, the subject to be treated suffers from vasospasm associated with SAH. In some embodiments, the subject to be treated has suffered trauma that results in vasospasm (e.g., trauma that results in SAH). The methods can comprise administering to a subject in need thereof an effective amount of a nitric oxide precursor. In some embodiments, the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof. In some embodiments, the subject to be treated is suffering from vasospasm associated with SAH. In some embodiments, the nitric oxide precursor, such as citrulline, is administered orally. In some embodiments, the nitric oxide precursor, such as citrulline, is administered intravenously.
- It is therefore an object of the presently disclosed subject matter to provide for treatment for SAH, vasospasm, and/or associated complications in a subject.
- An object of the presently disclosed subject matter having been stated hereinabove, other objects will become evident as the description proceeds, when taken in connection with the accompanying drawings and examples as best described hereinbelow.
-
FIG. 1 is a schematic of the urea cycle. - A considerable number of people worldwide are afflicted with Aneurysmal Subarachnoid Hemorrhage (SAH). The mortality rate for this condition is quite high, and even patients who survive SAH frequently experience dramatic reductions in their qualities of life. Current therapies in use can often prevent the death of a person who has experienced SAH if begun within an appropriate timeframe, but even successfully preventing that patient's death does not address the development of serious secondary complications. Therapies aimed at preventing secondary complications such as vasospasm and its sequelae, for example, are provided in accordance with aspects of the presently disclosed subject matter.
- The in vivo synthetic pathway for arginine commences with ornithine. Ornithine is combined with carbamyl phosphate to produce citrulline, which in turn is combined with aspartate, in the presence of adenosine triphosphate (ATP), to produce argininosuccinate. In the final step, fumarate is split from argininosuccinate, to produce arginine. The degradative pathway for arginine is by the hydrolytic action of arginase, to produce ornithine and urea. These reactions form the urea cycle. The urea cycle serves as the primary pathway for removing waste nitrogen produced by the metabolism of endogenous and exogenous proteins, and is shown schematically in
FIG. 1 . In addition to its role in nitrogen clearance, the urea cycle is the body's intrinsic source of arginine which acts as a precursor of nitric oxide (NO), a potent vasodilator. - SAH typically results from rupture of a cranial aneurysm which results in leakage of blood into compartments of the nervous system that contain cerebrospinal fluid. Primary symptomology typically includes sudden onset of headache, which is usually very severe, nausea, vomiting, neck pain, photophobia, and loss of consciousness (Suarez et al. (2006) N Engl J Med 354:387-396), which is frequently associated with neurological deficits that become apparent on physical exam (Suarez et al. (2006) N Engl J Med 354:387-396). Hydrocephalus (20%), rebleeding (7%), cerebral vasospasm (46%), seizures (30%), hyponatremia (28%), myocardial injury (35%), and pulmonary edema (23%) occur in a significant percentage of patients, even if the damage to the underlying vessel(s) is repaired. These events also frequently lead to additional secondary complications, including seizures, pulmonary edema, cardiac arrhythmias, electrolyte disturbances, and neuropsychological complications such as problems with memory, mood, and neuropsychological function.
- While the causes of the various sequelae of SAH are multifactorial, certain observations have been made. For example, decreased availability of nitric oxide in cerebral vessels has been observed, as has increased synthesis of endothelin or increase sensitivity of the arteries to this factor. Alterations in smooth muscle cells that promote a contracted state and activation of signal transduction mechanisms that can alter calcium sensitivity have also been reported. Additionally, increased thrombogenicity of the endothelium and/or platelet adhesion contributing to arterial dysfunction can occur, as can disruption of the blood brain barrier, inflammation, vasoconstriction, and injury to cerebral vessels of all sizes.
- Given its devastating impact on patients, rapid diagnosis and treatment of SAH is critical. Typically, patients presenting with symptoms suggestive of SAH are subjected to head CT, which can detect the presence of SAH. If a subarachnoid hemorrhage is detected, FT angiography and/or cerebral angiography can locate an aneurysm, which is then repaired. If, however, the angiography is normal, CT angiography is typically repeated 1-3 weeks subsequent to initial presentation, optionally followed by brain, brain stem, and/or spinal cord imaging. In those cases where heat CT does not detect a subarachnoid hemorrhage, testing of cerebrospinal fluid obtained by lumbar puncture can also provide indicators of SAH, which then can be confirmed by angiography.
- Once SAH is diagnosed, treatment generally includes securing of the aneurysm by neurosurgical clipping or endovascular coiling. Treatment of associated symptoms including, but not limited to hypertension, hyperthermia, hyperglycemia, and ischemia are performed as needed. Given that complications associated with SAH typically develop over the course of several weeks, a subject generally remains hospitalized for extended periods in order to provide continuous monitoring of the subject's condition.
- The presently disclosed subject matter provides methods for treating SAH and/or associated complications in a subject. In some embodiments, an effective amount of a nitric oxide precursor is administered to a subject suffering from SAH and/or associated complications and/or at risk for suffering complications associated with SAH. Representative examples of such complications are disclosed herein above.
- In some embodiments, the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof. See
FIG. 1 . In some embodiments, the nitric oxide precursor is selected from the group including, but not limited to, citrulline, arginine, or combinations thereof. In some embodiments, the nitric oxide precursor, such as citrulline, is administered orally. In some embodiments, the nitric oxide precursor, such as citrulline, is administered intravenously. In some embodiments, the subject to be treated is a subject suffering from vasospasm. In some embodiments, the subject to be treated is a subject suffering from an acute condition associated with vasospasm. Representative examples of such conditions are disclosed herein above. - In some embodiments, the subject suffering from a complication, such as vasospasm, suffers from relative hypocitrullinemia. The term “relative hypocitrullinemia” refers to a state in which the subject suffering from a complication has reduced plasma citrulline as compared to a subject not suffering from a complication.
- In some embodiments, the subject suffers from hypocitrullinemia. In some embodiments the hypocitrullinemia is characterized by plasma citrulline levels of ≦37 μmol/liter, in some embodiments, ≦25 μmol/liter, in some embodiments, ≦20 μmol/liter, in some embodiments, ≦10 μmol/liter, in some embodiments, ≦5 μmol/liter.
- The presently disclosed subject matter also provides methods and compositions for treating vasospasm. In some embodiments, the subject to be treated suffers from vasospasm associated with SAH. In some embodiments, the subject to be treated has suffered trauma that results in vasospasm (e.g., trauma that results in SAH). In some embodiments the vasospasm is associated with atherosclerosis in the subject. In some embodiments the atherosclerosis is associated with coronary artery disease in the subject, with carotid arterial disease in the subject, with peripheral arterial disease in the subject, and combinations thereof.
- In some embodiments, the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof. See
FIG. 1 . In some embodiments, the nitric oxide precursor is selected from the group including, but not limited to, citrulline, arginine, or combinations thereof. In some embodiments, the nitric oxide precursor, such as citrulline, is administered orally. In some embodiments, the nitric oxide precursor, such as citrulline, is administered intravenously. In some embodiments, the subject to be treated is a subject suffering from vasospasm. In some embodiments, the subject to be treated is a subject suffering from an acute condition associated with vasospasm (e.g. ischemia and/or angina in coronary arterial disease). - In some embodiments, the subject suffering from a complication, such as vasospasm, suffers from relative hypocitrullinemia. The term “relative hypocitrullinemia” refers to a state in which the subject suffering from a complication has reduced plasma citrulline as compared to a subject not suffering from a complication.
- As used herein, the phrase “treating” refers to both intervention designed to ameliorate a condition in a subject (e.g., after initiation of a disease process or after an injury) as well as to interventions that are designed to prevent the condition from occurring in the subject. Stated another way, the terms “treating” and grammatical variants thereof are intended to be interpreted broadly to encompass meanings that refer to reducing the severity of and/or to curing a condition, as well as meanings that refer to prophylaxis. In this latter respect, “treating” can refer to “preventing” to any degree, or otherwise enhancing the ability of the subject to resist the process of the condition, such as a subject at risk to suffer the condition.
- The subject treated in the presently disclosed subject matter in its many embodiments is desirably a human subject, although it is to be understood that the principles of the presently disclosed subject matter indicate that the presently disclosed subject matter is effective with respect to all vertebrate species, including warm-blooded vertebrates such as mammals and birds, which are intended to be included in the term “subject”. In this context, a mammal is understood to include any mammalian species in which treatment is desirable, such as but not limited to agricultural and domestic mammalian species.
- Thus, provided is the treatment of mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also provided is the treatment of birds, including the treatment of those kinds of birds that are endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans. Thus, provided is the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.
- An effective dose of a composition of the presently disclosed subject matter is administered to a subject in need thereof. An “effective amount” is an amount of a composition sufficient to produce a measurable response (e.g., a biologically or clinically relevant response in a subject being treated). Actual dosage levels of active ingredients in the compositions of the presently disclosed subject matter can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular subject. The selected dosage level will depend upon the activity of the therapeutic composition, the route of administration, combination with other drugs or treatments, the severity of the condition being treated, and the condition and prior medical history of the subject being treated. By way of example and not limitation, doses of compositions can be started at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. The potency of a composition can vary, and therefore an “effective amount” can vary.
- After review of the disclosure of the presently disclosed subject matter presented herein, one of ordinary skill in the art can tailor the dosages to an individual subject, taking into account the particular formulation, method of administration to be used with the composition, and particular disease treated. Further calculations of dose can consider subject height and weight, gender, severity and stage of symptoms, and the presence of additional deleterious physical conditions.
- By way of additional examples, the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the subject to be treated and the particular mode of administration. For example, a formulation intended for administration to humans can contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. For example, in a human adult, the doses per person per administration are generally between 1 mg and 500 mg up to several times per day. Thus, dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
- The nitric oxide precursor is administered in some embodiments in a dose ranging from about 0.01 mg to about 1,000 mg, in some embodiments in a dose ranging from about 0.5 mg to about 500 mg, and in some embodiments in a dose ranging from about 1.0 mg to about 250 mg. The nitric oxide precursor can also be administered in some embodiments in a dose ranging from about 100 mg to about 30,000 mg, and in some embodiments in a dose ranging from about 250 mg to about 1,000 mg. A representative dose is 3.8 g/m2/day of arginine or citrulline (molar equivalents, MW L-citrulline 175.2, MW L-arginine 174.2).
- Representative intravenous citrulline solutions can comprise a 100 mg/ml (10%) solution. Representative intravenous citrulline dosages can comprise 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg. In some embodiments, for example but not limited to a 600 or 800 mg/kg dosage, the dose can be decreased by an amount ranging from 50 mg/kg and 100 mg/kg to mitigate observed undesired effects on systemic blood pressure. In some embodiments, doses can be administered one or more times during a given period of time, such as a day.
- In some embodiments a pharmaceutical composition comprises an amount of citrulline effective to raise plasma citrulline level to treat a complication as disclosed herein in a subject. In some embodiments, the level is determined by comparing plasma citrulline levels in a subject to be treated to that observed in a subject not suffering from the complication. In some embodiments, the amount of citrulline is effective to raise plasma citrulline level in a subject to at least 5 μmol/liter, optionally at least 10 μmol/liter, optionally at least 20 μmol/liter, optionally at least 25 μmol/liter, and optionally about 37 μmol/liter.
- In some embodiments, the presently disclosed subject matter provides pharmaceutical compositions comprising a nitric oxide precursor and a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable carrier in humans. In some embodiments, the presently disclosed subject matter provides pharmaceutical compositions comprising citrulline or arginine in dosages as described above.
- A composition of the presently disclosed subject matter is typically administered orally or parenterally in dosage unit formulations containing standard nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. The term “parenteral” as used herein includes intravenous, intra-muscular, intra-arterial injection, or infusion techniques.
- Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, are formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Exemplary carriers include neutral saline solutions buffered with phosphate, lactate, Tris, and the like.
- In a representative embodiment doses can be administered to a subject several times during a relevant treatment period, including but not limited to 1, 2, 3, 4, 5, 6 or more dosages.
- It will be understood, however, that the specific dose level for any particular subject will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
- The following Examples have been included to illustrate representative modes of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only in that numerous changes, modification, and alterations can be employed without departing from the spirit and scope of the presently disclosed subject matter.
- While symptom management plays a major role in the treatment of SAH, there continues to be a long felt need for treatment strategies that address the underlying physiological bases for the development of secondary complications of SAH. For example, one of the key pathological mechanisms following aneurismal SAH is decreased availability of nitric oxide in cerebral vessels resulting in contraction of smooth muscles or vasospasm. By comparing plasma from patients with and without vasospasm it has been determined by the instant co-inventors there is a significant difference in citrulline levels such that patients with vasospasm have lower levels of citrulline as compared to patients without vasospasm. While it is not desired to be bound by any particular theory of operation, these results suggest that citrulline acting as a NO precursor can be a treatment for both SAH and coronary arterial disease through a similar mechanism of supporting vascular relaxation through restoring an adequate supply of citrulline which can act as a nitric oxide precursor amongst other actions.
- Examples 1 and 2 present the results of assaying plasma levels of citrulline, ornithine, arginine, and nitric oxide in subjects with and without vasospasm. The samples were separated by 24 hours in time from collection. In Example 1, levels were assayed after early collection, and in Example 2, levels were assayed after late collection.
-
-
COMPARISON OF PLASMA (EARLY COLLECTION) IN PATIENTS WITHOUT AND WITH VASOSPASM Parameter Without vasospasm1 With vasospasm1 p-value Citrulline (nM/ml) 9.12 ± 1.2 5.66 ± 1.2 0.08 Ornithine (nM/ml) 31.66 ± 5.7 16.46 ± 3.4 0.04 Arginine (nM/ml) 34.88 ± 9.7 22.54 ± 4.3 0.14 Nitric Oxide (μM) 27.36 ± 4.8 30.72 ± 9.6 0.38 1n = 5; data expressed as mean ± standard error -
-
COMPARISON OF PLASMA (LATE COLLECTION) IN PATIENTS WITHOUT AND WITH VASOSPASM Parameter Without vasospasm With vasospasm1 p-value Citrulline (nM/ml) 8.62 ± 1.2 4.81 ± 1.6 0.12 Ornithine (nM/ml) 42.60 ± 4.9 25.22 ± 6.5 0.06 Arginine (nM/ml) 47.76 ± 16 26.52 ± 9.0 0.14 Nitric Oxide (μM) 58.85 ± 39 48.01 ± 30 0.41 1n = 5; data expressed as mean ± standard error - The references listed below as well as all references cited in the specification are incorporated herein by reference to the extent that they supplement, explain, provide a background for or teach methodology, techniques and/or compositions employed herein.
- Batista da Costa Jr. et al. (2004) Arq Neuro-Psiquiatr (Sao Paulo) 62:245-249.
- Suarez et al. (2006)N Engl J Med 354:387-396.
- Flett et al. (2005) AJNR Am J Neuroradiol 26:367-372.
- Published U.S. Patent Application Number US-2004-0235953-A1, published Nov. 25, 2004.
- PCT International Patent Application Publication No. WO 2005/082042, published Sep. 9, 2005.
- U.S. Pat. No. 6,343,382.
- U.S. Pat. No. 6,743,823.
- It will be understood that various details of the presently disclosed subject matter may be changed without departing from the scope of the presently disclosed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.
Claims (18)
1. A method of treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
2. The method of claim 1 , wherein the subject has suffered trauma that results in SAH.
3. The method of claim 1 , wherein the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof.
4. The method of claim 1 , wherein the administering is intravenously or orally.
5. The method of claim 1 , wherein the nitric oxide precursor is administered in a dose ranging from about 100 mg to about 30,000 mg.
6. The method of claim 5 , wherein the nitric oxide precursor is administered in a dose ranging from about 250 mg to about 1,000 mg.
7. A method of treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
8. The method of claim 7 , wherein the vasospasm is associated with aneurysmal subarachnoid hemorrhage in the subject.
9. The method of claim 7 , wherein the subject has suffered trauma that results in vasospasm.
10. The method of claim 7 , wherein the vasospasm is associated with atherosclerosis in the subject.
11. The method of claim 10 , wherein the atherosclerosis is associated with coronary arterial disease, with carotid arterial disease, with peripheral arterial disease, or combinations thereof.
12. The method of claim 7 , wherein the nitric oxide precursor comprises at least one of citrulline, a precursor that generates citrulline in vivo, a pharmaceutically acceptable salt thereof, and combinations thereof.
13. The method of claim 7 , wherein the administering is intravenously or orally.
14. The method of claim 7 , wherein the nitric oxide precursor is administered in a dose ranging from about 100 mg to about 30,000 mg.
15. The method of claim 14 , wherein the nitric oxide precursor is administered in a dose ranging from about 250 mg to about 1,000 mg.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of citrulline effective to raise plasma citrulline level to treat a complication associated with aneurysmal subarachnoid hemorrhage (SAH) or vasospasm in a subject, wherein the level is determined by comparing plasma citrulline levels in a subject to be treated to that observed in a subject not suffering from a complication associated with aneurysmal subarachnoid hemorrhage (SAH) or vasospasm.
17. The pharmaceutical composition of claim 16 , wherein the amount of citrulline effective to raise plasma citrulline level in a subject to at least 5 μmol/liter, optionally at least 10 μmol/liter, optionally at least 20 μmol/liter, optionally at least 25 μmol/liter, and optionally about 37 μmol/liter.
18. The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is adapted for intravenous or oral administration.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/322,434 US20090197964A1 (en) | 2008-01-31 | 2009-02-02 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US13/331,678 US9943494B2 (en) | 2008-01-31 | 2011-12-20 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US15/955,370 US10500181B2 (en) | 2008-01-31 | 2018-04-17 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2517008P | 2008-01-31 | 2008-01-31 | |
US12/322,434 US20090197964A1 (en) | 2008-01-31 | 2009-02-02 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,678 Continuation US9943494B2 (en) | 2008-01-31 | 2011-12-20 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090197964A1 true US20090197964A1 (en) | 2009-08-06 |
Family
ID=40932329
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/322,434 Abandoned US20090197964A1 (en) | 2008-01-31 | 2009-02-02 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US13/331,678 Active US9943494B2 (en) | 2008-01-31 | 2011-12-20 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US15/955,370 Active US10500181B2 (en) | 2008-01-31 | 2018-04-17 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,678 Active US9943494B2 (en) | 2008-01-31 | 2011-12-20 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US15/955,370 Active US10500181B2 (en) | 2008-01-31 | 2018-04-17 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
Country Status (16)
Country | Link |
---|---|
US (3) | US20090197964A1 (en) |
EP (1) | EP2240170B1 (en) |
JP (2) | JP5623916B2 (en) |
KR (2) | KR20100135728A (en) |
CN (2) | CN102369006A (en) |
AU (2) | AU2009212693B2 (en) |
BR (1) | BRPI0906608A2 (en) |
CA (1) | CA2715260C (en) |
DK (1) | DK2240170T3 (en) |
ES (1) | ES2732810T3 (en) |
HU (1) | HUE045571T2 (en) |
PL (1) | PL2240170T3 (en) |
PT (1) | PT2240170T (en) |
RU (1) | RU2528097C2 (en) |
SG (1) | SG196863A1 (en) |
WO (1) | WO2009099999A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040235953A1 (en) * | 1999-06-01 | 2004-11-25 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US20090312423A1 (en) * | 2008-01-31 | 2009-12-17 | Vanderbilt University | Therapeutic treatment for lung conditions |
US8188147B2 (en) | 1999-06-01 | 2012-05-29 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US9943494B2 (en) | 2008-01-31 | 2018-04-17 | Vanderbilt University | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017015664A (en) | 2015-06-29 | 2018-04-18 | Univ Vanderbilt | Intravenous administration of citrulline during surgery. |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4769331A (en) * | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4996236A (en) * | 1988-06-22 | 1991-02-26 | Takeda Chemical Industries, Ltd. | Therapeutic composition for hepatic encephalopathy |
US5162215A (en) * | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5286634A (en) * | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
US5286739A (en) * | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5489742A (en) * | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
US5550316A (en) * | 1991-01-02 | 1996-08-27 | Fox Chase Cancer Center | Transgenic animal model system for human cutaneous melanoma |
US5550024A (en) * | 1991-04-19 | 1996-08-27 | Biotechnology Research & Development Corporation | Genetic markers for pig litter size |
US5573933A (en) * | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
US5614396A (en) * | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5625125A (en) * | 1994-08-09 | 1997-04-29 | Dnx Biotherapeutics | Phospholipase A2 expressing transgenic animals |
US5641484A (en) * | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
US5643567A (en) * | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
US5648061A (en) * | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
US5651964A (en) * | 1990-12-04 | 1997-07-29 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by the adenoviral EIA gene |
US5741957A (en) * | 1989-12-01 | 1998-04-21 | Pharming B.V. | Transgenic bovine |
US5767160A (en) * | 1994-10-05 | 1998-06-16 | Notol, Inc. | Method and formulation of stimulating nitric oxide synthesis |
US5874471A (en) * | 1997-02-27 | 1999-02-23 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US5873359A (en) * | 1990-12-05 | 1999-02-23 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
US6343382B2 (en) * | 1999-06-14 | 2002-02-05 | Kevin Sciglia | Hat |
US6346382B1 (en) * | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
US6358536B1 (en) * | 1997-10-15 | 2002-03-19 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
US20030134332A1 (en) * | 2001-11-28 | 2003-07-17 | Boykin Joseph V. | Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
US20040235953A1 (en) * | 1999-06-01 | 2004-11-25 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US20060194728A1 (en) * | 2005-01-06 | 2006-08-31 | Anthony Killian | Surfactant treatment regimen |
US20070026448A1 (en) * | 2001-09-07 | 2007-02-01 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human G-protein coupled receptor, HBPRBMY39 |
US20070184554A1 (en) * | 2005-12-01 | 2007-08-09 | Nps Allelix Corp. | Biomarker of improved intestinal function |
US20090312423A1 (en) * | 2008-01-31 | 2009-12-17 | Vanderbilt University | Therapeutic treatment for lung conditions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
NL8102724A (en) | 1980-07-11 | 1982-02-01 | Stamicarbon | PROCESS FOR PREPARING COPOLYMERS OF ETHENE WITH AT LEAST ANOTHER 1-OLEENE |
US5374651A (en) | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
US5334380A (en) | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US5385940A (en) | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
AU6232794A (en) | 1993-01-29 | 1994-08-15 | Brigham And Women's Hospital | The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6028107A (en) * | 1997-02-27 | 2000-02-22 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US6796966B2 (en) | 1997-10-15 | 2004-09-28 | Jeffrey E. Thomas | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
JP3506114B2 (en) | 2000-01-25 | 2004-03-15 | 株式会社ニコン | MONITOR DEVICE, POLISHING APPARATUS HAVING THE MONITOR DEVICE, AND POLISHING METHOD |
RU2202269C2 (en) * | 2001-02-14 | 2003-04-20 | Жильвинас Закарявичюс | Method for predicting surgical treatment results in middle age patients in the cases of acute intracranial hemorrhages of aneurysmal nature |
US6899140B2 (en) | 2002-08-12 | 2005-05-31 | Wellstream International Limited | Flexible pipe and method of manufacturing same using metal reinforced tape |
JP5623916B2 (en) * | 2008-01-31 | 2014-11-12 | バンダービルト・ユニバーシティVanderbilt University | Pharmaceutical composition for aneurysmal subarachnoid hemorrhage and vasospasm |
US20090291066A1 (en) | 2008-05-22 | 2009-11-26 | Apostolos Pappas | composition and method of treating facial skin defect |
-
2009
- 2009-02-02 JP JP2010545246A patent/JP5623916B2/en active Active
- 2009-02-02 DK DK09708687.0T patent/DK2240170T3/en active
- 2009-02-02 PL PL09708687T patent/PL2240170T3/en unknown
- 2009-02-02 SG SG2014005458A patent/SG196863A1/en unknown
- 2009-02-02 PT PT09708687T patent/PT2240170T/en unknown
- 2009-02-02 CN CN2009801091471A patent/CN102369006A/en active Pending
- 2009-02-02 CA CA2715260A patent/CA2715260C/en active Active
- 2009-02-02 US US12/322,434 patent/US20090197964A1/en not_active Abandoned
- 2009-02-02 EP EP09708687.0A patent/EP2240170B1/en active Active
- 2009-02-02 ES ES09708687T patent/ES2732810T3/en active Active
- 2009-02-02 WO PCT/US2009/032826 patent/WO2009099999A2/en active Application Filing
- 2009-02-02 HU HUE09708687A patent/HUE045571T2/en unknown
- 2009-02-02 AU AU2009212693A patent/AU2009212693B2/en active Active
- 2009-02-02 KR KR1020107019291A patent/KR20100135728A/en active Search and Examination
- 2009-02-02 KR KR1020167036885A patent/KR101932831B1/en active IP Right Grant
- 2009-02-02 BR BRPI0906608-0A patent/BRPI0906608A2/en not_active Application Discontinuation
- 2009-02-02 CN CN201510522527.5A patent/CN105106186A/en active Pending
- 2009-02-02 RU RU2010132580/15A patent/RU2528097C2/en not_active Application Discontinuation
-
2011
- 2011-12-20 US US13/331,678 patent/US9943494B2/en active Active
-
2014
- 2014-07-18 AU AU2014204508A patent/AU2014204508B2/en active Active
- 2014-09-25 JP JP2014195084A patent/JP6042392B2/en active Active
-
2018
- 2018-04-17 US US15/955,370 patent/US10500181B2/en active Active
Patent Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4769331A (en) * | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US4683202B1 (en) * | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195B1 (en) * | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5573933A (en) * | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
US4996236A (en) * | 1988-06-22 | 1991-02-26 | Takeda Chemical Industries, Ltd. | Therapeutic composition for hepatic encephalopathy |
US5162215A (en) * | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5286634A (en) * | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
US5741957A (en) * | 1989-12-01 | 1998-04-21 | Pharming B.V. | Transgenic bovine |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5614396A (en) * | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5489742A (en) * | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
US5643567A (en) * | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
US5651964A (en) * | 1990-12-04 | 1997-07-29 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by the adenoviral EIA gene |
US5641484A (en) * | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
US5873359A (en) * | 1990-12-05 | 1999-02-23 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
US5550316A (en) * | 1991-01-02 | 1996-08-27 | Fox Chase Cancer Center | Transgenic animal model system for human cutaneous melanoma |
US5550024A (en) * | 1991-04-19 | 1996-08-27 | Biotechnology Research & Development Corporation | Genetic markers for pig litter size |
US5286739A (en) * | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
US20020013288A1 (en) * | 1993-06-11 | 2002-01-31 | Cooke John P. | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6337321B1 (en) * | 1993-06-11 | 2002-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6646006B2 (en) * | 1993-06-11 | 2003-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6642208B2 (en) * | 1993-06-11 | 2003-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
US5625125A (en) * | 1994-08-09 | 1997-04-29 | Dnx Biotherapeutics | Phospholipase A2 expressing transgenic animals |
US5767160A (en) * | 1994-10-05 | 1998-06-16 | Notol, Inc. | Method and formulation of stimulating nitric oxide synthesis |
US5648061A (en) * | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
US5874471A (en) * | 1997-02-27 | 1999-02-23 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US6358536B1 (en) * | 1997-10-15 | 2002-03-19 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
US6346382B1 (en) * | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
US6743823B1 (en) * | 1999-06-01 | 2004-06-01 | Vanderbilt University | Therapeutic methods relating to human carbamyl phosphate synthetase I polymorphism |
US20040235953A1 (en) * | 1999-06-01 | 2004-11-25 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6343382B2 (en) * | 1999-06-14 | 2002-02-05 | Kevin Sciglia | Hat |
US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
US20070026448A1 (en) * | 2001-09-07 | 2007-02-01 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human G-protein coupled receptor, HBPRBMY39 |
US20030134332A1 (en) * | 2001-11-28 | 2003-07-17 | Boykin Joseph V. | Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
US20060194728A1 (en) * | 2005-01-06 | 2006-08-31 | Anthony Killian | Surfactant treatment regimen |
US20070184554A1 (en) * | 2005-12-01 | 2007-08-09 | Nps Allelix Corp. | Biomarker of improved intestinal function |
US20090312423A1 (en) * | 2008-01-31 | 2009-12-17 | Vanderbilt University | Therapeutic treatment for lung conditions |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8536225B2 (en) | 1999-06-01 | 2013-09-17 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US8188147B2 (en) | 1999-06-01 | 2012-05-29 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US20040235953A1 (en) * | 1999-06-01 | 2004-11-25 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US8956658B2 (en) | 2005-05-27 | 2015-02-17 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US11691995B2 (en) | 2005-05-27 | 2023-07-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8962029B2 (en) | 2005-05-27 | 2015-02-24 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9403852B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9403851B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US10500181B2 (en) | 2008-01-31 | 2019-12-10 | Vanderbilt University | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US20090312423A1 (en) * | 2008-01-31 | 2009-12-17 | Vanderbilt University | Therapeutic treatment for lung conditions |
US9943494B2 (en) | 2008-01-31 | 2018-04-17 | Vanderbilt University | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US9737561B2 (en) | 2009-08-21 | 2017-08-22 | Novan, Inc. | Topical gels and methods of using the same |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US10376538B2 (en) | 2009-08-21 | 2019-08-13 | Novan, Inc. | Topical gels and methods of using the same |
US11583608B2 (en) | 2009-08-21 | 2023-02-21 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
US9713652B2 (en) | 2011-02-28 | 2017-07-25 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10500181B2 (en) | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage | |
Galland | Magnesium, stress and neuropsychiatric disorders | |
US20090137565A1 (en) | Method for treatment of movement disorders | |
US20060088517A1 (en) | Compounds and methods for treating seizure disorders | |
US6596756B1 (en) | Treatment of fibromyalgia | |
US20060287253A1 (en) | Compounds and methods for treating seizure disorders | |
KR20190039227A (en) | Therapeutics for neurodegenerative diseases | |
KR20190039226A (en) | Pharmaceutical compositions and uses related to lysosomal accumulation diseases | |
MXPA00012808A (en) | The use of valproic acid analog for the treatment and prevention of migraine and affective illness. | |
US20020077355A1 (en) | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions | |
KR20200074170A (en) | Treatment for neurodegenerative diseases | |
Fotuhi et al. | The effects of obesity on brain structure and size | |
US7776913B2 (en) | Carnitines for treating or preventing disorders caused by andropause | |
KR20200121819A (en) | Treatment for Restless Leg Syndrome | |
TW202207944A (en) | Treatment for depression | |
US8835503B2 (en) | Pharmaceutical composition containing GLUR2-lacking AMPAR antagonist for preventing or treating psychiatric illnesses | |
US20220098291A1 (en) | Treatment of Parkinson's Disease | |
Warrit | Perianesthesia analgesia, recovery efficacy, and financial impact of ultrasound-guided lumbar plexus and sciatic nerve analgesia in dogs undergoing tibial plateau leveling osteotomy | |
WO2023215344A2 (en) | Compositions and methods for treating cluster-tic syndrome | |
JP2017507941A (en) | Novel composition for treating mechanical nerve injury | |
Scher | Diagnosis and treatment of neonatal seizures | |
CHECK | 2.81 Galantamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VANDERBILT UNIVERSITY, TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUMMAR, MARSHALL L.;BARR, FREDERICK E.;THOMPSON, REID;REEL/FRAME:022333/0159;SIGNING DATES FROM 20090209 TO 20090210 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |